CHICAGO — The much-anticipated first trial in the comprehensive litigation over Zantac’s alleged cancer-causing ingredients commenced Thursday, setting the stage for plaintiff Angela Valadez’s grievous claims against pharmaceutical giants. In a Chicago courtroom, filled to the brim, the 89-year-old Illinois woman’s attorneys argued that her prolonged use of the heartburn medication directly led to her colorectal cancer.
Plaintiff To Share ‘Horrific’ Story In First Zantac Cancer Trial: Plaintiff’s Struggle with Cancer Linked to Zantac
Angela Valadez, who used over-the-counter Zantac and its generic form, ranitidine, from 1995 until 2014, alleges that the presence of nitrosodimethylamine (NDMA), a known carcinogen in lab animals, is to blame for her cancer. Valadez’s harrowing experiences, which she plans to detail personally, include severe symptoms such as diarrhea, nausea, and significant abdominal pain, painting a vivid portrait of her daily struggles.
Her legal team argued that GlaxoSmithKline and Boehringer Ingelheim, the drug’s manufacturers, failed in their duty to ensure the safety of Zantac, neglecting to inform consumers of its dangerous contents.
Plaintiff To Share ‘Horrific’ Story In First Zantac Cancer Trial: Courtroom Packed, Overflowing with Observers
The gravity of the case drew such a large audience that court officials were forced to open additional rooms to accommodate the crowd. This turnout underscores the significant public and legal interest in the implications of this trial concerning consumer safety and corporate responsibility.
Defense Challenges the Claims
Representatives for the defendants argued that Valadez’s lifestyle and other health factors, including previous smoking habits and diabetes, might have contributed to her cancer. They stressed that no conclusive scientific evidence links NDMA in Zantac to cancer in humans, describing the case against them as “unfair and untrue.”
Legal and Scientific Scrutiny Intensifies
The trial, expected to last three to four weeks, is just the beginning of a series of lawsuits facing the manufacturers of Zantac and generic ranitidine. Despite a federal judge dismissing claims against several manufacturers in December 2022, the ongoing litigation in state courts, including this high-profile case in Illinois, continues to challenge these findings.
